Importance of dose-schedule of 5-aza-2′-deoxycytidine for epigenetic therapy of cancer

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Lemaire, Maryse ^a   Chabot, Guy G ^b   Raynal, Noël J M ^a   Momparler, Louise F ^a   Hurtubise, Annie ^a   Bernstein, Mark L ^c   Momparler, Richard L ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Centre National de la Recherche Scientifique   (France)

^c Hematology Oncology IWK Health center   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P16; ANTINEOPLASTIC AGENT; AZACITIDINE; CYCLIN DEPENDENT KINASE INHIBITOR; DRUG DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CANCER SURVIVAL; CELL STRAIN HL 60; CLONOGENESIS; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG POTENCY; EPIGENETICS; GENE ACTIVATION; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; LUNG CANCER; LYMPHATIC LEUKEMIA; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPTIMAL DRUG DOSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL; DRUG ADMINISTRATION; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENETIC EPIGENESIS; GENETICS; GENOME IMPRINTING; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZACITIDINE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIGENESIS, GENETIC; GENOMIC IMPRINTING; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; NEOPLASMS, EXPERIMENTAL; TUMOR STEM CELL ASSAY;

EID: 44149125758     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-128     Document Type: Article

References (41)

1. Jones PA Laird PW Cancer epigenetics comes of age Nat Genet 1999, 21:163-167. 10.1038/5947 9988266
2. Jones PA Baylin SB The fundamental role of epigenetic events in cancer Nat Rev Genet 2002, 3:415-428. 10.1038/nrg962 12042769
3. Momparler RL Bovenzi V DNA methylation and cancer J Cell Physiol 2000, 183:145-154. 10.1002/ (SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V 10737890
4. Momparler RL Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine) Semin Oncol 2005, 32:443-451. 10.1053/j.seminoncol.2005.07.008 16210084
5. Momparler RL Pharmacology of 5-Aza-2′-deoxycytidine (decitabine) Semin Hematol 2005, 42:S9-16. 10.1053/j.seminhematol.2005.05.002 16015507
6. Momparler RL Gonzales FA Effect of intravenous infusion of 5-aza-2′-deoxycytidine on survival time of mice with L1210 leukemia Cancer Res 1978, 38:2673-2678. 79443
7. Wilson VL Jones PA Momparler RL Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2′-deoxycytidine as a possible mechanism of chemotherapeutic action Cancer Res 1983, 43:3493-3496. 6190553
8. Lemaire M Momparler LF Bernstein ML Marquez VE Momparler RL Enhancement of antineoplastic action of 5-aza-2′-deoxycytidine by zebularine on L1210 leukemia Anticancer Drugs 2005, 16:301-308. 10.1097/ 00001813-200503000-00009 15711182
9. Braakhuis BJ van Dongen GA van Walsum M Leyva A Snow GB Preclinical antitumor activity of 5-aza-2′-deoxycytidine against human and neck cancer xenografts [corrected] Invest New Drugs 1988, 6:299-304. 10.1007/BF00173648 2466014
10. Jones PA Taylor SM Cellular differentiation, cytidine analogs and DNA methylation Cell 1980, 20:85-93. 10.1016/0092-8674(80)90237-8 6156004
11. Momparler RL Dore BT Momparler LF Effect of 5-aza-2′-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells Cancer Lett 1990, 54:21-28. 10.1016/ 0304-3835(90)90086-D 1698532
12. Pinto A Attadia V Fusco A Ferrara F Spada OA Di Fiore PP 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias Blood 1984, 64:922-929. 6206904
13. Issa JP Garcia-Manero G Giles FJ Mannari R Thomas D Faderl S Bayar E Lyons J Rosenfeld CS Cortes J Kantarjian HM Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies Blood 2004, 103:1635-1640. 10.1182/blood-2003-03-0687 14604977
14. Kantarjian HM O'Brien S Cortes J Giles FJ Faderl S Issa JP Garcia-Manero G Rios MB Shan J Andreeff M Keating M Talpaz M Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia Cancer 2003, 98:522-528, 10.1002/cncr.11543 12879469
15. Wijermans P Lubbert M Verhoef G Bosly A Ravoet C Andre M Ferrant A Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients J Clin Oncol 2000, 18:956-962. 10694544
16. Ruter B Wijermans PW Lubbert M Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients Cancer 2006, 106:1744-1750. 10.1002/cncr.21796 16532502
17. Kantarjian H Issa JP Rosenfeld CS Bennett JM Albitar M DiPersio J Klimek V Slack J de Castro C Ravandi F Helmer R 3rd Shen L Nimer SD Leavitt R Raza A Saba H Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study Cancer 2006, 106:1794-1803. 10.1002/cncr.21792 16532500
18. Rivard GE Momparler RL Demers J Benoit P Raymond R Lin K Momparler LF Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia Leukemia research 1981, 5:453-462. 10.1016/0145-2126(81)90116-8 6173545
19. van Groeningen CJ Leyva A O'Brien AM Gall HE Pinedo HM Phase I and pharmacokinetic study of 5-aza-2′-deoxycytidine (NSC 127716) in cancer patients Cancer Res 1986, 46:4831-4836. 2425959
20. Samlowski WE Leachman SA Wade M Cassidy P Porter-Gill P Busby L Wheeler R Boucher K Fitzpatrick F Jones DA Karpf AR Evaluation of a 7-day continuous intravenous infusion of decitabine: Inhibition of promoter-specific and global genomic DNA methylation J Clin Oncol 2005, 23:3897-3905. 10.1200/JCO.2005.06.118 15753459
21. Schrump DS Fischette MR Nguyen DM Zhao M Li X Kunst TF Hancox A Hong JA Chen GA Pishchik V Figg WD Murgo AJ Steinberg SM Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura Clin Cancer Res 2006, 12:5777-5785. 10.1158/1078-0432.CCR-06-0669 17020984
22. Momparler RL Bouffard DY Momparler LF Dionne J Belanger K Ayoub J Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer Anti-Cancer Drugs 1997, 8:358-368. 10.1097/00001813-199704000-00008 9180389
23. Rockwell SC Kallman RF Fajardo LF Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative J Natl Cancer Inst 1972, 49:735-749. 4647494
24. Otterson GA Khleif SN Chen W Coxon AB Kaye FJ CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine Oncogene 1995, 11:1211-1216. 7566983
25. Brenner AJ Stampfer MR Aldaz CM Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation Oncogene 1998, 17:199-205. 10.1038/ sj.onc.1201919 9674704
26. Yang AS Estecio MR Doshi K Kondo Y Tajara EH Issa JP A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements Nucleic Acids Res 2004, 32:e38. 373427 14973332 10.1093/nar/ gnh032
27. Rockwel SC Tumor-Cell Survival Tumor Models in Cancer Research Totowa (NJ): Humana Press Teicher BA 2002, 617-631.
28. Hsu JC Peruggia M Graphical representation of Tukey's multiple comparison method J Computational Graphical Statistics 1994, 3:143-161. 10.2307/1390666
29. Chabot GG Momparler RL Antileukemic activity of 5-aza-2′-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia Cancer Treat Rep 1984, 68:1483-1487. 6210142
30. Momparler RL Samson J Momparler LF Rivard GE Cell cycle effects and cellular pharmacology of 5-aza-2′-deoxycytidine Cancer Chemother Pharmacol 1984, 13:191-194. 10.1007/BF00269027 6207950
31. Momparler RL Momparler LF Samson J Comparison of the antileukemic activity of 5-Aza-2′-deoxycytidine, 1-β-D-arabinofuranosyl-cytosine and 5-azacytidine against L1210 leukemia Leukemia Res 1984, 8:1043-1049. 10.1016/0145-2126(84)90059-6
32. Mayer RJ Davis RB Schiffer CA Berg DT Powell BL Schulman P Omura GA Moore JO McIntyre OR Frei E Intensive postremission chemotherapy in adults with acute myeloid leukemia New Engl J Med 1994. 331:896-903. 10.1056/NEJM199410063311402 8078551
33. Kvinlaug BT Huntly BJP Targeting cancer stem cells Expert Opin Ther Targets 2007, 11:915-927. 10.1517/14728222.11.7.915 17614760
34. Tannock IF Lee CM Tunggal JK Cowan DSM Egorin MJ Limited penetration of anticancer drugs through tissue: A potential cause of resistance of solid tumors to chemotherapy Clin Cancer Res 2002, 8:878-884. 11895922
35. Chabot GG Momparler RL Pharmacokinetics of 5-aza-2′-deoxycytidine in animals and man: Relevance to clinical trials 5-Aza-2′-deoxycytidine: Preclinical and clinical studies Haarlem, (Netherlands): PCH Dick de Vos, Richard L Momparler 1990, 105-115.
36. Momparler RL Cote S Eliopoulos N Pharmacological approach for optimization of the dose schedule of 5-Aza-2′-deoxycytidine (Decitabine) for the therapy of leukemia Leukemia 1997, 11(Suppl 1):1-6. 9130684
37. Skipper HE Schabel FM Jr Mellett LB Montgomery JA Wilkoff LJ Lloyd HH Brockman RW Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules Cancer Chemother Rep 1970 54 431 450 5527023
38. Primeau M Gagnon J Momparler RL Synergistic antineoplastic action of DNA methylation inhibitor 5-aza-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells Intl J Cancer 2003, 103:177-184. 10.1002/ijc.10789
39. Lemaire M Momparler LF Farinha NJ Bernstein M Momparler RL Enhancement of Antineoplastic Action of 5-Aza-2′-deoxycytidine by Phenylbutyrate on L1210 Leukemic Cells Leukemia & Lymphoma 2004, 45:147-154. 10.1080/1042819031000149304 15061212
40. Dokmanovic M Clarke C Marks PA Histone deacetylase inhibitors: Overview and perspectives Mol Cancer Res 2007, 5:981-989. 10.1158/ 1541-7786.MCR-07-0324 17951399
41. Piekarz RL Sackett DL Bates SE Histone deacetylase inhibitors and demethylating agents: Clinical development of histone deacetylase inhibitors for cancer therapy Cancer J 2007, 13:30-39. 17464244